Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s claim about increased risk of hepatic decompensation and hepatotoxicity in chronic hepatitis C is directly supported by the provided FDA label sections 5.1 and 5.2, including the associated clinical trial findings and counseling/monitoring context.
Category Scores
Accurate Statements
Risk of hepatic decompensation and hepatotoxicity in chronic hepatitis C
Supported by 5.1 (hepatic decompensation in chronic hepatitis C with interferon/ribavirin) and 5.2 (hepatotoxicity risk).
In chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation (including ascites and encephalopathy rates) and higher risk with low albumin (<3.5 g/dL) or MELD score >=10; discontinue PROMACTA if antiviral therapy is discontinued.
5.1 Hepatic Decompensation in Patients With Chronic Hepatitis C.
PROMACTA may increase the risk of severe and potentially life-threatening hepatotoxicity.
5.2 Hepatotoxicity.
Unsupported Statements
Contradictions
Important Omissions
The response does not explicitly mention the label’s liver-test monitoring schedule and the specific discontinuation laboratory criteria from section 5.2.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The audited claim is a safety risk stated in the label (hepatic decompensation and hepatotoxicity in chronic hepatitis C). No contradictory or fabricated safety assertions were added.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of specific monitoring frequency and lab-based discontinuation thresholds described in section 5.2.
Suggested Improvement
If expanding beyond the general risk statement, include the label’s monitoring schedule (ALT/AST/bilirubin timing) and the precise discontinuation criteria from section 5.2.